SpringWorks Therapeutics, a Phase 3 biotech developing small molecule therapies for rare cancers, raised $162 million by offering 9.0 million shares at $18, the high end of the range of $16 to $18.
SpringWorks Therapeutics plans to list on the Nasdaq under the symbol SWTX. J.P. Morgan, Goldman Sachs and Cowen acted as lead managers on the deal.
Rare cancer biotech SpringWorks Therapeutics prices IPO at $18 high end
September 12, 2019

